The Regulatory Countdown Has Begun
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) fundamentally altered the FDA's oversight of the cosmetics industry, introducing mandatory facility registration, product listing, adverse event reporting, and safety substantiation requirements. Among its most consequential—and least understood—provisions is the statutory directive requiring FDA to promulgate a rule identifying fragrance allergens that must be disclosed on cosmetic product labels.
Unlike many MoCRA provisions that took immediate effect, the fragrance allergen disclosure rule requires formal rulemaking. FDA has been working toward a proposed rule, and once issued, the agency will move through notice-and-comment procedures before finalizing binding requirements. For companies that manufacture, market, or distribute fragranced cosmetic products in the United States, the window to prepare is narrowing—and the cost of waiting until the rule is finalized is substantial.
What the Statute Requires
MoCRA directs FDA to identify fragrance allergens that must be individually disclosed on product labels when present above a specified threshold, rather than permitting them to remain generically listed as "fragrance" or "parfum." In developing this list, Congress instructed FDA to consider allergens already identified by other domestic and international authorities—a clear signal that the agency will look closely at existing frameworks rather than build an allergen list from scratch.
This matters enormously for compliance planning. The most developed and internationally recognized fragrance allergen framework already in force is the European Union's Cosmetic Products Regulation, which mandates disclosure of specific fragrance allergens on labels when concentrations exceed defined thresholds (generally 0.001% in leave-on products and 0.01% in rinse-off products). The International Fragrance Association (IFRA) also maintains standards restricting or requiring disclosure of numerous fragrance materials based on sensitization data.
Given this legislative history, sophisticated companies should assume that FDA's eventual list will substantially overlap with—though not necessarily mirror exactly—the EU's existing allergen roster.
Why Waiting Is a Costly Strategy
Companies that delay allergen auditing until after FDA issues a final rule face a compressed and expensive compliance timeline. Reformulation is rarely simple:
- Supply chain dependencies. Fragrance houses often treat exact formulations as proprietary, meaning brand owners may not have full visibility into allergen content without direct engagement with suppliers.
- Label and packaging lead times. Redesigning labels to accommodate new allergen disclosures—particularly for products with limited label real estate—can require months of design, legal review, and printer coordination.
- Multi-jurisdictional complexity. Companies selling into both the U.S. and EU markets must reconcile potentially divergent disclosure thresholds and allergen lists, increasing the risk of inconsistent labeling across markets.
- Retailer and distributor requirements. Many national retailers impose their own compliance deadlines ahead of regulatory effective dates, meaning market pressure often outpaces the government's own timeline.
Companies that wait for the final rule before beginning internal audits risk being forced into rushed reformulations, emergency relabeling runs, or temporary withdrawal of noncompliant SKUs—all of which are far more expensive than proactive planning.
A Proactive Audit Framework
Rather than waiting for regulatory certainty, companies should begin now to build the internal infrastructure necessary to respond quickly once FDA's proposed rule is published. A disciplined audit should include the following steps:
- Cross-reference existing formulations against the EU Annex III allergen list. Identify which products already contain allergens above EU disclosure thresholds, even if not currently required to disclose them under U.S. law.
- Engage fragrance suppliers for allergen transparency. Request detailed allergen composition data, including concentrations, for every fragrance blend used across the product portfolio. Confidentiality agreements can protect supplier trade secrets while still enabling internal compliance review.
- Map product labels against available label space. Evaluate whether current packaging can physically accommodate expanded allergen disclosures, and begin preliminary design work for labels that may require restructuring.
- Prioritize high-risk product categories. Leave-on products (lotions, perfumes, deodorants) generally carry lower allergen thresholds than rinse-off products, and should be reviewed first.
- Document safety substantiation records. MoCRA's broader safety substantiation requirement dovetails with allergen disclosure obligations; maintaining thorough documentation now strengthens the company's overall compliance posture.
- Establish a regulatory monitoring protocol. Assign responsibility for tracking FDA's rulemaking docket, comment periods, and any interim guidance, ensuring the company can respond promptly once the proposed rule is published.
Strategic Considerations for Multinational Brands
Companies already complying with EU fragrance allergen disclosure requirements hold a meaningful advantage, but should not assume full equivalence with the forthcoming U.S. rule. FDA retains discretion to adopt different concentration thresholds, disclosure formats, or allergen groupings tailored to U.S. market conditions and public comment. Brands should treat EU compliance as a strong starting point—not a substitute—for U.S.-specific analysis.
Companies should also anticipate that FDA will solicit public comments on the proposed rule, and active participation in that process can meaningfully shape the final requirements. Trade associations and individual companies alike have historically influenced threshold levels, allergen list scope, and compliance timelines through substantive comment submissions grounded in scientific and operational data.
Positioning for a Smooth Transition
The fragrance allergen labeling rule represents one of the more operationally demanding aspects of MoCRA implementation, precisely because it touches formulation, supply chain, packaging, and labeling functions simultaneously. Companies that begin internal audits now—benchmarking against EU standards, engaging suppliers for transparency, and stress-testing label design—will be positioned to implement final requirements efficiently rather than reactively.
Given the complexity of coordinating legal, regulatory, and operational teams around this transition, companies should consider engaging counsel experienced in MoCRA compliance to guide the audit process, review supplier agreements for allergen disclosure obligations, and prepare comments during the rulemaking process. Early legal engagement is often the difference between a controlled, cost-effective transition and a last-minute scramble driven by regulatory deadlines.